Efficacy of protease inhibitor monotherapyvs. triple therapy: meta‐analysis of data from 2303 patients in 13 randomized trials
Authors:
- 28 December 2015
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 17 (5) , 358-367
Abstract
Objectives: The aim of this analysis was to review the evidence and update a meta‐analysis evaluating the efficacy and safety results from randomized controlled trials of ritonavir‐boosted protease inhibitor (PI/r) monotherapy.Methods: A PubMed/EMBASEsearch was conducted to find randomized trials ofPI/r monotherapyvs. triple therapy in patients withHIV‐1RNAsuppression at baseline (n = 784:MONET,MONOI, Monarch andPROTEA), lopinavir/r monotherapy (n = 829:OKpilot,OK‐04, KalMo,KALESOLO,KRETA,MOSTandDREAM), atazanavir/r monotherapy (n = 103:MODAT), or all three (n = 587:PIVOT).HIV‐1RNAplasma suppression was lower in thePI/r monotherapy arm compared with the triple therapy arm in the switch‐equals‐failure analysis [difference −8.3%; 95% confidence interval (CI) −11.9 to −4.8%], but not when intensification was included (difference 0.5%; 95%CI−2.5 to 3.6%). Rates of resistance mutations were similar between arms, as was overall neurocognitive function.Conclusions: PI/r monotherapy showed a higher risk of plasmaHIV‐1RNAelevations. However, there was no increased risk of treatment‐emergent drug resistance, neurocognitive endpoints did not differ, andHIV‐1RNAsuppression rates after intensification were similar betweenPI/r monotherapy and triple therapy.Keywords
This publication has 30 references indexed in Scilit:
- Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trialInternational Journal of STD & AIDS, 2013
- Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meetingAIDS Research and Therapy, 2013
- Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 WeeksPLOS ONE, 2012
- The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baselineHIV Medicine, 2012
- Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 studyJournal of Antimicrobial Chemotherapy, 2011
- Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-AnalysisPLOS ONE, 2011
- Current understanding of HIV-associated neurocognitive disorders pathogenesisCurrent Opinion in Neurology, 2011
- Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136AIDS, 2010
- Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadirAIDS, 2010
- Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIVAIDS, 2008